

# **Golimumab Drug Level ELISA**

For the quantitative determination of free SIMPONI® concentration in human EDTA plasma and serum.

For Research Use Only. Not For Use In Diagnostic Procedures.

Catalog Number: 30-GOLHU-E01

Size: 96 Wells

**Version:** 2018-01-09 – ALPCO February 5, 2018

#### **INTENDED USE**

The Golimumab Drug Level ELISA is intended for the quantitative determination of free Golimumab (SIMPONI®) concentration in human EDTA plasma and serum. For research use only. Not for use in diagnostic procedures.

#### PRINCIPLE OF THE ASSAY

This ELISA is designed to determine the quantity of free golimumab (therapeutic antibody against TNF-alpha antibodies, SIMPONI®) in EDTA plasma or serum samples. In a first incubation step, the free golimumab from the sample is bound to the specific monoclonal anti-golimumab antibody coated on the plate. To remove all unbound substances, a washing step is carried out. In a further incubation step, peroxidase-labeled antibody is added. Tetramethylbenzidine (TMB) is used as a substrate for peroxidase. Finally, an acidic stop solution is added to terminate the reaction. The color changes from blue to yellow. The intensity of the yellow color is directly proportional to the concentration of free golimumab in the sample. A dose response curve of the absorbance unit (optical density, OD at 450 nm) vs. concentration is generated, using the values obtained from standard. The concentrations of free golimumab in the samples are determined directly from this curve.

#### **MATERIALS SUPPLIED**

| Component                                       | Quantity      | Preparation  |  |  |
|---|---------------|--------------|--|--|
| Microplate (96 wells)                           | 12 x 8 strips | Ready to use |  |  |
| Control Levels 1 + 2                            | 1 vial each   | Ready to use |  |  |
| Wash Buffer Concentrate                         | 100 mL        | 10X          |  |  |
| Standards 1-6 (0, 4.15, 8.3, 25, 75, 225 ng/mL) | 1 vial each   | Ready to use |  |  |
| Sample Buffer                                   | 100 mL        | Ready to use |  |  |
| Conjugate Concentrate                           | 200 μL        | 101X         |  |  |
| TMB Substrate                                   | 15 mL         | Ready to use |  |  |
| Stop Solution                                   | 15 mL         | Ready to use |  |  |

#### **MATERIALS REQUIRED**

- Precision pipettes for dispensing up to 1000 μL (with disposable tips)
- Repeating or multi-channel pipette for dispensing up to 1000 μL
- Volumetric containers and pipettes for reagent preparation
- Distilled/Deionized water for reagent preparation
- Microplate washer or wash bottle
- Microplate shaker capable of 550 rpm with an orbit of 2mm
- Microplate reader
- Centrifuge (1,000 xg to 3,000 xg)
- Vortex for sample preparation
- Laboratory balance
- Foil to cover the microplate
- Timer

#### **PRECAUTIONS**

- The human blood products incorporated into this kit have been tested for the presence of HIV (Human Immunodeficiency Virus), HBV (Hepatitis B Virus), and HCV (Hepatitis C Virus). Test methods for these viruses do not guarantee the absence of a virus; therefore, all reagents should be treated as potentially infectious. Handling and disposal should be in accordance with all appropriate national and local regulations for the handling of potentially biohazardous materials.
- 2. All materials derived from animal sources are bovine spongiform encephalopathy (BSE) negative. However, all materials should be treated as potentially infectious.
- 3. Kit reagents contain sodium azide or Proclin as bactericides. Sodium azide and Proclin are toxic. Substrates for the enzymatic color reactions are toxic and carcinogenic. Avoid contact with skin or mucous membranes.
- 4. The stop solution consists of diluted sulfuric acid, a strong acid. Although diluted, it still must be handled with care. It can cause burns and should be handled with gloves, eye protection, and appropriate protective clothing. Any spill should be wiped up immediately with copious quantities of water. Do not breathe vapor and avoid inhalation.
- 5. Avoid direct contact with skin.
- 6. This product is not for internal use.
- 7. Avoid eating, drinking, or smoking when using this product.
- 8. Do not pipette any reagents by mouth.
- 9. Reagents from this kit are lot-specific and must not be substituted.
- 10. Do not use reagents beyond the expiration date.
- 11. Variations to the test procedure are not recommended and may influence the test results.

#### **STORAGE CONDITIONS**

The kit should be stored at 2-8°C. The kit is stable until the expiration date on the box label.

#### SAMPLE HANDLING

Serum and EDTA Plasma are appropriate for use with this assay.

EDTA plasma or serum samples must be diluted 1:100 before performing the assay, e.g., 10  $\mu$ L sample + 990  $\mu$ L Sample Dilution Buffer, mix well. Pipet 100  $\mu$ L of each prepared sample per well.

## Sample storage

Freshly collected EDTA plasma or serum can be stored for one day at room temperature (15–30 °C) or for longer storage at -20 °C.

#### **REAGENT PREPARATION**

All reagents must be equilibrated to room temperature prior to preparation and subsequent use in the assay. Prepare enough reagents for only the number of strips used. Reagents with a volume less than 100  $\mu$ L should be centrifuged before use to avoid loss of volume.

Wash Buffer Concentrate (10X) must be diluted with distilled water 1:10 before use (100 mL wash buffer + 900 mL distilled water) and mixed well. Crystals could occur due to high salt concentration in the stock solutions. The crystals must be dissolved at room temperature or in a water bath at 37 °C before dilution of the buffer solutions. The undiluted wash buffer is stable at

2–8 °C until the expiry date stated on the label. Wash buffer (1:10 diluted wash buffer) can be stored in a closed flask at 2–8 °C for one month.

**Conjugate Concentrate** must be diluted 1:101 in wash buffer (100 µL conjugate concentrate + 10 mL wash buffer). The undiluted conjugate is stable at 2–8 °C until expiry date stated on the label. Conjugate (1:101 diluted conjugate) is not stable and cannot be stored.

All other test reagents are ready to use. Test reagents are stable until the expiry date (see kit label) when stored at 2–8 °C.

#### **QUALITY CONTROL**

Control samples should be analyzed with each run. Results generated from the analysis of control samples, should be evaluated for acceptability using appropriate statistical methods. The results for the samples may not be valid if within the same assay one or more values of the quality control sample are outside the acceptable limits.

#### **ASSAY PROCEDURE**

All reagents and microplate strips (while sealed in foil pouch) should be equilibrated to room temperature prior to use. Gently mix all reagents before use. A standard curve must be performed with each assay run and with each microplate if more than one is used at a time. All standards, controls, and samples should be run in duplicate.

For automated ELISA processors, the given protocol may need to be adjusted according to the specific features of the respective automated platform. For further details please contact ALPCO.

- 1. Add 100 µL of standard, sample or controls into the respective wells.
- 2. Cover the plate tightly and incubate for 1 hour at room temperature (15–30 °C) on a horizontal shaker set to 550 rpm with an orbit of 2mm.
- 3. Discard the contents of each well. Wash each well 5x by dispensing 250 µL of wash buffer into each well. After the final washing step remove residual buffer by tapping the plate on absorbent paper.
- 4. Add 100 µL diluted conjugate into each well.
- 5. Cover the plate tightly and incubate for 1 hour at room temperature (15–30 °C) on a horizontal shaker set to 550 rpm with an orbit of 2mm.
- 6. Discard the contents of each well. Wash each well 5x by dispensing 250 µL of wash buffer into each well. After the final washing step remove residual buffer by tapping the plate on absorbent paper.
- 7. Add 100 µL substrate into each well.
- 8. Incubate for 10–20 min\*\* at room temperature (15–30 °C) in the dark.
- 9. Add 100 µL stop solution into each well, mix.
- 10. Determine absorption immediately with an ELISA reader at 450 nm against 620 nm (or 690 nm) as a reference. If no reference wavelength is available, read only at 450 nm. If the extinction of the highest standard exceeds the range of the photometer, absorption must be measured immediately at 405 nm against 620 nm as a reference.

\*\*The intensity of the color change is temperature sensitive. It is recommended to observe the color change and to stop the reaction upon good differentiation.

#### **CALCULATION OF RESULTS**

The following algorithms can be used alternatively to calculate the results. It is recommended to use a 4-parameter algorithm.

- 1. 4-parameter algorithm: It is recommended to use a linear ordinate for the optical density and a logarithmic abscissa for the concentration. When using a logarithmic abscissa, the zero calibrator must be specified with a value less than 1 (e.g. 0.001).
- 2. Point-to-point calculation: It is recommended to use a linear ordinate for the optical density and a linear abscissa for the concentration.
- 3. Spline algorithm: It is recommended to use a linear ordinate for the optical density and a linear abscissa for the concentration.

The plausibility of the pairs of values should be examined before the automatic evaluation of the results. If this option is not available with the program used, a comparison of the paired values should be done manually.

#### EDTA plasma and serum samples.

The obtained golimumab levels of EDTA plasma and serum samples have to be multiplied with the dilution factor of 100. In case another dilution factor has been used, multiply the obtained result with the dilution factor used.

#### **LIMITATIONS**

Samples with concentrations above the measurement range must be further diluted and reassayed. Please consider this greater dilution when calculating the results. Samples with concentrations lower than the measurement range cannot be clearly quantified.

The upper limit of the measurement range can be calculated as:

highest concentration of the standard curve × sample dilution factor to be used

The lower limit of the measurement range can be calculated as:

LoB × sample dilution factor to be used

#### PERFORMANCE CHARACTERISTICS

#### **Analytical Sensitivity**

The LoB (limit of blank) was evaluated according to the guideline CLSI EP17-A2 and was calculated as 3.56 ng/mL.

### Precision: Within run (intra-assay) variation (n=19)

The precision (intra-assay variation) was calculated from 19 replicate determinations on three samples.

| Sample | Golimumab<br>(µg/mL) | CV % |
|--------|----------------------|------|
| 1      | 6.2                  | 6.6  |
| 2      | 15.2                 | 6.4  |
| 3      | 7.8                  | 4.1  |

# Precision: Between run (inter-assay) variation (n=11)

The total precision (inter-assay variation) was calculated from data on two samples obtained in 11 different assays.

| Sample | Golimumab<br>(μg/mL) | CV % |
|--------|----------------------|------|
| 1      | 13.8                 | 5.3  |
| 2      | 6.5                  | 5.0  |

# **Spiking Recovery**

| Probe | Unspiked<br>Sample (µg/mL) | Spike (µg/mL) | Expected<br>Golimumab<br>(µg/mL) | Measured<br>Golimumab<br>(μg/mL) |  |
|-------|----------------------------|---------------|----------------------------------|----------------------------------|--|
|       | 0.33                       | 10.0          | 10.33                            | 10.85                            |  |
| А     | 0.33                       | 5.0           | 5.33                             | 5.52                             |  |
|       | 0.33                       | 2.5           | 2.83                             | 3.20                             |  |

# **Dilutional Linearity**

| Sample | Dilution | Expected<br>Golimumab<br>(µg/mL) | Measured<br>Golimumab<br>(µg/mL) |  |  |
|--------|----------|----------------------------------|----------------------------------|--|--|
|        | 1:200    | 14.07                            | 14.07                            |  |  |
|        | 1:400    | 7.04                             | 7.60                             |  |  |
|        | 1:800    | 3.52                             | 4.05                             |  |  |
| Α      | 1:1600   | 1.76                             | 2.07                             |  |  |
|        | 1:3200   | 0.88                             | 1.01                             |  |  |
|        | 1:6400   | 0.44                             | 0.57                             |  |  |
|        | 1:200    | 8.22                             | 8.22                             |  |  |
|        | 1:400    | 4.11                             | 4.06                             |  |  |
| В      | 1:800    | 2.06                             | 2.13                             |  |  |
| _      | 1:1600   | 1.03                             | 1.09                             |  |  |
|        | 1:3200   | 0.51                             | 0.61                             |  |  |
|        | 1:200    | 6.44                             | 6.44                             |  |  |
|        | 1:400    | 3.22                             | 3.33                             |  |  |
| С      | 1:800    | 1.61                             | 1.59                             |  |  |
|        | 1:1600   | 0.81                             | 0.86                             |  |  |
|        | 1:3200   | 0.40                             | 0.40                             |  |  |

#### **TECHNICAL HINTS**

- Do not interchange different lot numbers of any kit component within the same assay. Furthermore, it is recommended to not assemble wells of different microtiter plates for analysis, even if they are of the same batch.
- Control samples should be analyzed with each run.
- Reagents should not be used beyond the expiration date stated on kit label.
- Substrate solution should remain colorless until use.
- To ensure accurate results, proper adhesion of plate sealers during incubation steps is necessary.
- Avoid foaming when mixing reagents.
- Do not mix plugs and caps from different reagents.
- The assay should always be performed according to the enclosed manual.

#### **GENERAL NOTES ON THE ASSAY AND ASSAY PROCEDURE**

Incubation time, incubation temperature and pipetting volumes of the components are defined by the producer. Any variation of the test procedure, which is not coordinated with the producer, may influence the results of the test. ALPCO cannot be held responsible for any damage resulting from incorrect use.

#### SHORT ASSAY PROTOCOL



**Total Time = 2 hours 20 minutes** 

#### SUGGESTED PLATE LAYOUT

Below is a suggested plate layout for running standards, controls, and up to 40 samples in duplicate.

|   | 1      | 2      | 3 | 4 | 5  | 6  | 7  | 8  | 9  | 10 | 11 | 12 |
|---|--------|--------|---|---|----|----|----|----|----|----|----|----|
| Α | Std 1  | Std 1  | 1 | 1 | 9  | 9  | 17 | 17 | 25 | 25 | 33 | 33 |
| В | Std 2  | Std 2  | 2 | 2 | 10 | 10 | 18 | 18 | 26 | 26 | 34 | 34 |
| С | Std 3  | Std 3  | 3 | 3 | 11 | 11 | 19 | 19 | 27 | 27 | 35 | 35 |
| D | Std 4  | Std 4  | 4 | 4 | 12 | 12 | 20 | 20 | 28 | 28 | 36 | 36 |
| Е | Std 5  | Std 5  | 5 | 5 | 13 | 13 | 21 | 21 | 29 | 29 | 37 | 37 |
| F | Std 6  | Std 6  | 6 | 6 | 14 | 14 | 22 | 22 | 30 | 30 | 38 | 38 |
| G | Ctrl 1 | Ctrl 1 | 7 | 7 | 15 | 15 | 23 | 23 | 31 | 31 | 39 | 39 |
| Н | Ctrl 2 | Ctrl 2 | 8 | 8 | 16 | 16 | 24 | 24 | 32 | 32 | 40 | 40 |

Std= Standard Ctrl = Control

Numbered wells = Samples

<sup>\*</sup>It is recommended to set the plate shaker to 550rpm with an orbit of 2mm.